Entrada Therapeutics, Inc. Common Stock (TRDA) is a publicly traded Healthcare sector company. As of September 6, 2026, TRDA trades at $7.10 with a market cap of $277.62M and a P/E ratio of -1.79. TRDA moved -1.12% today. Year to date, TRDA is -32.10%; over the trailing twelve months it is +34.78%. Its 52-week range spans $4.93 to $16.45. Analyst consensus is strong buy with an average price target of $17.00. Rallies surfaces TRDA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for TRDA, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $7.10 |
| Market Cap | $277.62M |
| P/E Ratio | -1.79 |
| EPS | $-3.96 |
| Dividend Yield | 0.00% |
| 52-Week High | $16.45 |
| 52-Week Low | $4.93 |
| Volume | 285.03K |
| Avg Volume | 0 |
| Revenue (TTM) | $4.69M |
| Net Income | $-165.78M |
| Gross Margin | 0.00% |
5 analysts cover TRDA: 0 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $17.00.